Clinical Trial Update: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing nivolumab plus ipilimumab versus nivolumab alone in advanced renal cell carcinoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING